Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIVHCV Genotype 3 Patients 英文参考文献.docVIP

下载本文档

2
0
约2.71万字
约 6页
2017-05-11 发布于上海
举报
版权申诉

Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIVHCV Genotype 3 Patients 英文参考文献.doc

1、本文档共6页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIVHCV Genotype 3 Patients 英文参考文献

DifferencesinHCVViralDeclinebetweenLowand Standard-DosePegylated-Interferon-Alpha-2awith RibavirininHIV/HCVGenotype3Patients AntonioRivero-Jua′rez1,2,LuisF.Lopez-Cortes3,AngelaCamacho1,2,AlmudenaTorres-Cornejo3, JuanA.Pineda4,ManuelMarquez-Solero5,AntonioCaruz6,RosaRuiz-Valderas3,JulianTorre- Cisneros1,2,AliciaGutierrez-Valencia3,AntonioRivero1,2* 1Unit of Infectious Diseases, Hospital Universitario Reina Sofia, Cordoba, Spain, 2Maimonides Institute for Biomedical Research, Cordoba, Spain, 3Enfermedades Infecciosas, Microbiolog?′a y Medicina Preventiva, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc?′o/Consejo Superior de Investigaciones Cient?′ficas/Universidad de Sevilla, Seville, Spain, 4Unit of Infectious Diseases, Hospital Universitario de Valme, Seville, Spain, 5Unit of Infectious Diseases, Hospital UniversitarioVirgendelaVictoria,Malaga,Spain,6ImmunogeneticsUnit,FacultyofSciences,UniversidaddeJae′n,Jaen,Spain Abstract Background:Theaimofthestudywastoanalyzethedifferentimpactofstandardandlow-dosePeg-IFN-a2a/RBVtherapies onHCVviraldeclineinHIV/HCVgenotype3co-infectedpatientsduringthefirstweeksoftreatment. Methods:PlasmaHCVviraldeclinewasanalyzedbetweenbaselineandweeks1,2and4intwogroupsoftreatment-na?¨ve HCVgenotype3patientswithHIVco-infection.TheStandardDoseGroup(SDG)includedpatientswhoreceivedPeg-IFNat 180mg/perweekwithaweight-adjusteddoseofribavirin;Low-DoseGroup(LDG)patientsreceivedPeg-IFNat135 mg/per weekwith800mg/dayribavirin.TheeffectofIL28BgenotypeonHCVviraldeclinewasevaluatedinbothgroups.HCVviral declinewasanalyzedusingamultivariatelinearregressionmodel. Results: One hundred and six patients were included: 48 patients in the SDG and 58 in the LDG. HCV viral decline for IU/mL, patients in the LDG was less than for those in the SDG (week 1:1.7260.74 log10 IU/mL versus 1.7860.67 log10 p=0.827; week 2:2.360.89 log10 IU/mL versus 3.0161.02 log10 IU/mL, p=0.013; week 4:3.5261.2 log10 IU/mL versus 4.0961.1log10IU/mL,p=0.0